Etevritamab (AMG 596) is an EGFRvIII x CD3 bispecific T-cell engager (BiTE), AMG 596 is composed of two single-chain variable fragments that simultaneously bind to the tumor-specific antigen EGFR variant III (EGFRvIII) on GBM cells and to CD3 on T cells.
Etevritamab (AMG 596) activates T cells to proliferate and secrete cytotoxic substances, induces lysis of the bound tumor cell.
Etevritamab (AMG 596) is very potent and highly specific in vitro with EC50 values in the low picomolar range.
Etevritamab (AMG 596) treatment significantly increased the overall survival of mice bearing EGFRvIII-expressing orthotopic tumors, causes T-cell activation and T-cell-dependent lysis of GBM cells in vivo.
Isotype: Immunoglobulin scFv-scFv.
Anti-[human EGFR (epidermal growth factor receptor, receptor tyrosineprotein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)
variant III (EGFRvIII)] and anti-[human CD3E (CD3 epsilon, Leu-4)], monoclonal antibody single chain, bispecific.